Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity.
Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate the efficacy of a s...
主要な著者: | Jayne, DR, Chapel, H, Adu, D, Misbah, S, O'Donoghue, D, Scott, D, Lockwood, C |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
2000
|
類似資料
-
Placebo-controlled trial of intravenous immunoglobulin in ANCA-associated systemic vasculitis.
著者:: Jayne, D, 等
出版事項: (1999) -
Cardiovascular outcomes in ANCA associated vasculitis
著者:: Mukhtyar, C, 等
出版事項: (2008) -
Diagnosis and management of ANCA associated vasculitis.
著者:: Berden, A, 等
出版事項: (2012) -
Comparison of disease activity measures for ANCA-associated vasculitis.
著者:: Merkel, P, 等
出版事項: (2004) -
Explaining fatigue in ANCA-associated vasculitis.
著者:: Basu, N, 等
出版事項: (2013)